A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults
| Autor: | Anne-Claude Cremieux, Christine Katlama, Catherine Gillotin, Didier Demarles, Geoffrey J Yuen, Francois Raffi, AZL10002 Study Group |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Metabolic Clearance Rate HIV Infections Pharmacology Zidovudine Pharmacokinetics immune system diseases Abacavir medicine Humans Pharmacology (medical) Cross-Over Studies Reverse-transcriptase inhibitor business.industry virus diseases Lamivudine Abacavir/Lamivudine Lamivudine/Zidovudine Crossover study Dideoxynucleosides Drug Combinations Area Under Curve HIV-1 Reverse Transcriptase Inhibitors Drug Therapy Combination business medicine.drug Half-Life Tablets |
| Zdroj: | Pharmacotherapy. 21(4) |
| ISSN: | 0277-0008 |
| Popis: | Study Objective. To investigate the steady-state pharmacokinetics of a triple combination tablet containing abacavir (ABC) 300 mg, lamivudine (3TC) 150 mg, and zidovudine (ZDV) 300 mg taken twice/day, and those of ABC 300 mg twice/day plus a double combination tablet containing 3TC 150 mg and ZDV 300 mg twice/day (ABC-COM). Design. Open-label, crossover study. Setting. Two hospital-based clinical research units. Patients. Twelve men infected with human immunodeficiency virus-1. Intervention. Steady-state pharmacokinetics of ABC, 3TC, and ZDV were assessed after dosing with ABC-COM and the triple combination tablet. Measurements and Main Results. Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 μg·hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 μg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour. The GM half-lives of ABC and ZDV were similar for both treatments, 1.69 versus 1.58 and 2.30 versus 2.08 hours, respectively. Conclusion. Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar in patients who took them as ABC-COM or as a triple combination tablet. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text